This is a 4-month randomized open-label comparative safety, tolerability, and effectiveness
trial of Lithium versus Quetiapine for subjects presenting in any phase of Bipolar who
currently require a medication change for their illness. Stratified randomization will reduce
bipolar type I , bipolar type II , or sub-threshold imbalance across cells. The enrollment
goal is 60 subjects, over 24 months from initial regulatory approval. The primary outcome is
the difference between lithium and quetiapine in the time to 'all cause' medication
discontinuation.